Yes. Qiagen agreed on October 21, 2026 to be taken private by EQT Private Equity through an all-cash public takeover offer of €46.50 per share, a 40.3% premium to the unaffected price, valuing the company at about €10.8 billion including net debt. At the November 10, 2026 EUR/USD rate of 1.1222, the offer is worth about $52.18 per share. $QGEN closed at $50.51 on the NYSE that day, which leaves a spread of roughly 3.3%. Both Qiagen boards back the deal, the financing is committed and closing is expected in mid-2027. Shares cannot be tendered yet, because the offer document is still waiting on German regulatory approval.
The Qiagen takeover terms at a glance
The buyer is Crown NL Bidco B.V., and the terms come from the joint Qiagen and EQT press release and the Business Combination Agreement Qiagen filed with the SEC.
- Price: €46.50 in cash per share, without interest. Holders who own shares through a U.S. custodian will get a settlement process that lets them receive U.S. dollars.
- Minimum acceptance: 50% of Qiagen's outstanding share capital plus one share.
- Other conditions: shareholders must approve the Post-Closing Measures at an extraordinary general meeting (EGM), the boards must take a separate "Implementation Decision", and merger-control and foreign-investment clearances must be obtained.
- Financing: committed equity and debt, with no financing condition. The agreement puts the equity commitments at €5,966.9 million.
- Break fees: under the Business Combination Agreement, Qiagen would pay €150 million in specified cases, such as walking away for a superior proposal. The buyer would pay a €300 million reverse fee if the deal fails on competition or investment-screening approvals.
- Deadlines: closing is expected in mid-2027, and the agreement's long stop date is 15 months after signing.
| Date | Figure | Value |
|---|---|---|
| Jul 8, 2026 | XETRA close, last day before buyout reports (unaffected) | €33.15 |
| 3 months to Jul 8, 2026 | XETRA volume-weighted average price | €31.66 |
| Jul 8, 2026 | $QGEN NYSE close | $38.00 |
| Oct 20, 2026 | $QGEN close, day before the announcement | $48.90 |
| Oct 21, 2026 | $QGEN close, announcement day | $50.00 |
| Nov 10, 2026 | $QGEN close | $50.51 |
| Nov 10, 2026 | EUR/USD | 1.1222 |
| Nov 10, 2026 | €46.50 offer in dollars (approximate) | $52.18 |
NYSE closes are from Yahoo Finance. The euro reference prices are those quoted in the offer announcement.
Who is buying Qiagen
Crown NL Bidco is a holding company indirectly controlled by the EQT XI fund. Two co-investors hold indirect stakes: Luxinva S.A., a wholly owned subsidiary of the Abu Dhabi Investment Authority (ADIA), and CPP Investment Board Europe, a subsidiary of Canada Pension Plan Investment Board. That gives Canadian readers a direct link to the deal, since CPP Investments manages the Canada Pension Plan Fund, which totaled C$863.6 billion at June 30, 2026.
EQT reports €354 billion in assets under management. Its current and past healthcare holdings include Galderma, Parexel, Aldevron, Dako and HemoCue. The debt is being arranged by Morgan Stanley, Jefferies, Deutsche Bank, SMBC, Crédit Agricole and UniCredit.
The winner came out of a long auction. Bloomberg reported on July 9, 2026 that EQT, Advent and KKR were interested. Supervisory Board chairman Stephen H. Rusckowski said the boards weighed "discussions with strategic and financial parties" before choosing EQT. Our pre-deal breakdown of the Qiagen takeover talks tracks every report from January onward, and our October 4 piece covered the strategic-buyer chatter.
Premiums and valuation
EQT measures the headline premium against XETRA prices from before the July buyout reports. The price is 40.3% above the €33.15 close on July 8, 2026 (arithmetic: 46.50 ÷ 33.15 − 1 = 40.3%) and 46.9% above the €31.66 three-month VWAP (arithmetic: 46.50 ÷ 31.66 − 1 = 46.9%).
The deal carries an enterprise value of about €10.8 billion, or roughly $12.1 billion including about $1.1 billion of net debt. On the equity side, the agreement lists 206,800,617 issued shares, of which Qiagen held 304,096 in treasury. That leaves 206,496,521 shares outstanding, which at €46.50 comes to about €9.60 billion (arithmetic: 206,496,521 × 46.50), before any dilution from convertible notes or equity awards.
Qiagen released preliminary third-quarter numbers with the deal: net sales of $548 million and adjusted diluted EPS of $0.65. It suspended its full-year 2026 outlook while the transaction is pending, so there is no fresh standalone guidance to set against the bid. The only price figure from the run-up was Bloomberg's report that some suitors might pay "at least $50" a share. At current exchange rates the deal clears that by about 4.4% (arithmetic: 52.18 ÷ 50.00 − 1).
$QGEN in dollars: the spread to the offer
The offer is fixed in euros, but $QGEN trades in dollars, so its dollar value moves with the currency. The figures below are approximate for that reason.
- Offer in dollars: €46.50 × 1.1222 = $52.18.
- Gross spread: $52.18 − $50.51 = $1.67, or 3.3% of the $50.51 close (arithmetic: 1.67 ÷ 50.51).
- Same spread in euros: $50.51 ÷ 1.1222 = €45.01, which is €1.49 below the offer.
- Currency sensitivity: each one-cent move in EUR/USD changes the dollar value by about $0.47 (arithmetic: 46.50 × 0.01). At the November 9 rate of 1.1147, the offer was worth $51.83.
The stock has stayed in a tight range since the announcement, closing between $50.17 and $50.86 from October 22 through November 10. As an illustration only: if closing fell on June 30, 2027, 232 days after November 10, the 3.3% gross spread would equal about 5.2% a year (arithmetic: 3.31 × 365 ÷ 232). The 10-year Treasury yield was 4.98% on November 10.
What the spread prices in
A gross return barely above the 10-year Treasury yield means the market sees a high chance the deal closes. Little is left to pay for the things that could still go wrong:
- Tender math: Thermo Fisher's 2020 offer lapsed with only 47.02% of shares tendered. Our breakdown of the failed 2020 bid covers it, and our comparison of the two bids sets out what changed this time.
- The EGM vote: the boards commit to the Implementation Decision if at least 80% of votes cast approve the Post-Closing Measures. Below that, they may still go ahead, and they can weigh votes from holders who bought after the announcement "with the aim of frustrating the transaction or pursuing event-driven hedge fund strategies."
- Regulators: the conditions name competition authorities, foreign-investment screening and CFIUS. The €300 million reverse fee would compensate Qiagen, not its shareholders.
- Currency: dollar-based holders carry EUR/USD risk until settlement.
A few terms work in holders' favor. If regulatory approvals are still pending 10 months after the announcement, Qiagen may pay an interim dividend of up to $0.47 a share, which would not be deducted from the offer price. If Qiagen switched to a superior proposal, it would owe EQT a €150 million break fee, a cost any rival bid would have to absorb. Holders who never tender would eventually receive a cash distribution equal to the offer price less withholding taxes, which the companies say may net less than tendering. This is general information, not tax or legal advice. Our step-by-step Qiagen takeover timeline walks through each stage. For more live deal coverage, see the Markets section or the Trading Tips For You homepage.
Bull/Bear Verdict
Bull Case: A board-recommended, fully financed €46.50 cash offer with a 50%-plus-one threshold, a €300 million reverse fee and a possible $0.47 interim dividend puts a defined value on $QGEN, about $52.18 at the November 10 exchange rate.
Bear Case: The 3.3% gross spread pays little for the risks: tender and EGM math that sank the 2020 deal, competition and CFIUS reviews running into mid-2027, euro moves that shift the dollar value and withholding tax for anyone left until the back-end.
FAQ
Is Qiagen being acquired?
Yes. On October 21, 2026, Qiagen signed a Business Combination Agreement with Crown NL Bidco, which is controlled by the EQT XI fund, for a €46.50-per-share all-cash takeover offer. Both Qiagen boards unanimously support it. The offer has not started yet.
How much is the Qiagen offer in US dollars?
About $52.18 per share at the November 10, 2026 EUR/USD rate of 1.1222. The figure moves with the exchange rate, by about $0.47 for every one-cent change. $QGEN closed at $50.51 that day.
When will the Qiagen takeover close?
The companies expect closing in mid-2027. As of November 11, 2026, BaFin had not yet approved the offer document, so the acceptance period has not opened.
What happens to $QGEN shares that are not tendered?
If the deal closes and the Post-Closing Measures go ahead, holders who did not tender get a cash distribution equal to the offer price less applicable withholding taxes. Qiagen's NYSE and Frankfurt listings would then be terminated.